ESMO 2017 | How does olaparib affect the quality of life of breast cancer patients?
The OlympiA study (NCT02032823) demonstrated the efficacy of olaparib in the treatment of breast cancer patients with germline BRCA 1/2 mutations. Here, Elzbieta Senkus-Konefka, MD, PhD from the Medical University of Gdansk, Gdansk, Poland discusses the effect that olaparib had on patient quality of life, an important factor in the treatment of cancer patients. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.
Get great new content delivered to your inboxSign up